Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.40 |
| ▸ | FDPS | P14324 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SIK1 | P57059 | 1/20 | 0.39 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.39 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.39 |
| ▸ | AGER | Q15109 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6285122 | 1.00 | POLB (0.45) | POLBNPC1RAB9AAPAF1MCL1 | |
| SCHEMBL6283673 | 0.82 | POLB (0.45) | POLBAPAF1MAPTGGPS1FDPS | |
| SCHEMBL20985903 | 0.82 | MAPT (0.60) | POLBAPAF1MAPTGGPS1FDPS | |
| SCHEMBL17042129 | 0.81 | NPC1 (0.43) | POLBNPC1RAB9AAPAF1MCL1 | |
| SCHEMBL861938 | 0.79 | NPC1 (0.63) | POLBNPC1RAB9AMAPTLMNA | |
| SCHEMBL6281552 | 0.78 | FGFR1 (0.52) | POLBNPC1RAB9AAPAF1MAPT | |
| SCHEMBL6176862 | 0.78 | NPSR1 (0.46) | POLBNPC1RAB9AAPAF1MAPT | |
| SCHEMBL6284404 | 0.78 | NPSR1 (0.46) | POLBNPC1RAB9AAPAF1MAPT | |
| SCHEMBL6176569 | 0.78 | APAF1 (0.68) | POLBAPAF1MAPTGGPS1FDPS | |
| SCHEMBL6175278 | 0.78 | APAF1 (0.68) | POLBAPAF1MAPTGGPS1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392280-A4 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1392280-A2 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | Abbott GmbH & Co. KG (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY | 2003-05-22 | — | — | US | disclosed |
| WO-2002089749-A2 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | ABBOTT GMBH & CO.KG (DE) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | CASP1, IRAK1, STS | POLB 4412/4885NPC1 1805/4885RAB9A 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.